k) An Open-Label Extensıon Study To Evaluate The Long-Term Safety, Tolerabılıty, And Effıcacy Of Marstacımab Prophylaxıs In Severe (Coagulatıon Factor Actıvıty 1%) Hemophılıa A Partıcıpants Wıth Or Wıthout Inhıbıtors Or Moderately Severe To Severe Hemophılıa B Partıcıpants (Coagulatıon Factor Actıvıty ≤2%) Wıth Or Wıthout Inhıbıtors